IL308597A - A method for treating chronic obstructive pulmonary disease with an ST2 antagonist - Google Patents

A method for treating chronic obstructive pulmonary disease with an ST2 antagonist

Info

Publication number
IL308597A
IL308597A IL308597A IL30859723A IL308597A IL 308597 A IL308597 A IL 308597A IL 308597 A IL308597 A IL 308597A IL 30859723 A IL30859723 A IL 30859723A IL 308597 A IL308597 A IL 308597A
Authority
IL
Israel
Prior art keywords
antagonist
pulmonary disease
chronic obstructive
obstructive pulmonary
treating chronic
Prior art date
Application number
IL308597A
Other languages
English (en)
Hebrew (he)
Inventor
Michele Anne Grimbaldeston
Divya Mohan
Ahmed Yousuf
Christopher Brightling
Dorothy Sze-Wing Cheung
David Fong Choy
Original Assignee
Genentech Inc
Michele Anne Grimbaldeston
Divya Mohan
Ahmed Yousuf
Christopher Brightling
Cheung Dorothy Sze Wing
David Fong Choy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Michele Anne Grimbaldeston, Divya Mohan, Ahmed Yousuf, Christopher Brightling, Cheung Dorothy Sze Wing, David Fong Choy filed Critical Genentech Inc
Publication of IL308597A publication Critical patent/IL308597A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL308597A 2021-06-11 2022-06-10 A method for treating chronic obstructive pulmonary disease with an ST2 antagonist IL308597A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163209624P 2021-06-11 2021-06-11
PCT/US2022/032979 WO2022261417A1 (en) 2021-06-11 2022-06-10 Method for treating chronic obstructive pulmonary disease with an st2 antagonist

Publications (1)

Publication Number Publication Date
IL308597A true IL308597A (en) 2024-01-01

Family

ID=82458702

Family Applications (1)

Application Number Title Priority Date Filing Date
IL308597A IL308597A (en) 2021-06-11 2022-06-10 A method for treating chronic obstructive pulmonary disease with an ST2 antagonist

Country Status (12)

Country Link
US (1) US20240228638A1 (enExample)
EP (1) EP4352101A1 (enExample)
JP (1) JP2024522175A (enExample)
KR (1) KR20240019831A (enExample)
CN (1) CN117980333A (enExample)
AU (1) AU2022289017A1 (enExample)
BR (1) BR112023025863A2 (enExample)
CA (1) CA3221924A1 (enExample)
IL (1) IL308597A (enExample)
MX (1) MX2023014658A (enExample)
TW (1) TW202317622A (enExample)
WO (1) WO2022261417A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
CA3263546A1 (en) * 2022-08-08 2024-02-15 Verona Pharma Limited ENSIFENTRINE (RPL-554) FOR THE TREATMENT OF MODERATE CHRONIC OBSTRUCTIVE PULMONARY DISEASE
CN121620356A (zh) 2023-06-26 2026-03-06 维罗纳制药公司 包含恩塞芬汀的颗粒组合物
CN122121878A (zh) * 2023-09-06 2026-05-29 维罗纳制药有限公司 用于治疗慢性阻塞性肺病（copd）的恩塞芬汀
TW202540173A (zh) * 2024-04-04 2025-10-16 英商梅迪繆思有限公司 治療及選擇對象之方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
AU668349B2 (en) 1991-04-25 1996-05-02 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
EP0626012B1 (en) 1992-02-11 2003-07-09 Cell Genesys, Inc. Homogenotization of gene-targeting events
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
JP2002506353A (ja) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド ガラクトシル化糖タンパク質の方法及び組成物
CA2307166A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
EP1423510A4 (en) 2001-08-03 2005-06-01 Glycart Biotechnology Ag ANTIBODY GLYCOSYLATION VARIANTS WITH INCREASED ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
HUE038955T2 (hu) 2003-11-05 2018-12-28 Roche Glycart Ag Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2

Also Published As

Publication number Publication date
TW202317622A (zh) 2023-05-01
BR112023025863A2 (pt) 2024-03-05
CA3221924A1 (en) 2022-12-15
AU2022289017A1 (en) 2023-11-30
AU2022289017A9 (en) 2023-12-07
KR20240019831A (ko) 2024-02-14
US20240228638A1 (en) 2024-07-11
EP4352101A1 (en) 2024-04-17
JP2024522175A (ja) 2024-06-11
CN117980333A (zh) 2024-05-03
WO2022261417A1 (en) 2022-12-15
MX2023014658A (es) 2024-01-12

Similar Documents

Publication Publication Date Title
IL275840A (en) A method or system for quantifying a biomarker in tissue
GB2587032B (en) Method for designing accelerator hardware
ZA202108775B (en) New egfr inhibitors
IL287275A (en) Methods of treating or preventing asthma by administering an IL-33 agonist
EP3965681A4 (en) ALIGNMENT METHODS FOR COIL-SHAPED ABLATION ELECTRODES
GB2468073B (en) Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
IL310926A (en) Treatment of chronic obstructive pulmonary disease with anti-interleukin-33 antibody
AU2022298632A1 (en) Methods for treating obstructive sleep apnea
FI3952858T3 (fi) Menetelmä kasvainten hoitamiseksi
IL293544A (en) Methods for treating COPD by giving IL-33 antagonist
EP3643475A4 (en) METHOD FOR PREDICTING THE STRENGTH OF A STRUCTURE, METHOD FOR MANUFACTURING A STRUCTURE, METHOD TO SUPPORT THE STRUCTURE OF A STRUCTURE AND PROGRAM
EP3765025A4 (en) METHODS OF TREATMENT OF ASTHMA OR ALLERGY DISEASES
PL4368792T3 (pl) Sposób renowacji energetycznej budynku
EP3909445A4 (en) IN VITRO ASSESSMENT METHOD FOR THE RISK OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE ASSOCIATED WITH SMOKING OR INHALATION
IL287063A (en) A method for producing a similar structure-biotissue
SG11202005226VA (en) Method for producing anisotropic conductive sheet
IL287998A (en) Methods for the treatment of chronic obstructive pulmonary disease in an increased patient population using benralizumab
PH12014501272A1 (en) Method and vessel for laying a pipeline
IL304221A (en) A method for treating chronic kidney diseases
PL3543702T3 (pl) Sposoby badania przesiewowego osobnika pod kątem ryzyka przewlekłej choroby nerek i sposób realizowany komputerowo
GB202100372D0 (en) Method for processing web requests
CA3303794A1 (en) Ensifentrine for use in treating chronic obstructive pulmonary disease (copd)
GB202104287D0 (en) Method for determining prognosis of chronic kidney disease
GB2627013B (en) Computer implemented method
HK40064264A (en) Methods for treating chronic obstructive pulmonary disease in an enhanced patient population using benralizumab